^
    7d
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    8d
    PIVOT-006: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT (clinicaltrials.gov)
    P3, N=367, Active, not recruiting, CG Oncology, Inc. | Trial completion date: Jan 2030 --> Feb 2029 | Trial primary completion date: Jan 2028 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    cretostimogene grenadenorepvec (CG0070)
    12d
    Topical SGX302 for Mild-to-Moderate Psoriasis (clinicaltrials.gov)
    P2, N=15, Completed, Soligenix | N=47 --> 15 | Recruiting --> Completed
    Trial completion • Enrollment change
    12d
    A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, China Medical University, China | N=40 --> 60 | Trial completion date: Dec 2027 --> Dec 2028
    Enrollment change • Trial completion date
    |
    Loqtorzi (toripalimab-tpzi) • Stivarga (regorafenib)
    1m
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Replimune Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)
    1m
    Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (clinicaltrials.gov)
    P2, N=16, Recruiting, Lepu Biopharma Co., Ltd.
    New P2 trial
    |
    cretostimogene grenadenorepvec (CG0070)
    1m
    Emerging therapies for glioblastoma. (PubMed, J Neurooncol)
    Glioblastoma (GBM) remains associated with poor outcomes, with a median survival of 15-18 months despite maximal safe resection, radiotherapy, and temozolomide. CAR T-cell therapies are advancing toward bispecific and armored constructs with locoregional delivery, while oncolytic viruses such as DNX-2401 and PVSRIPO demonstrate potential for durable responses in select patients. Looking ahead, progress is likely to arise from biomarker-informed, multimodal regimens that integrate targeted agents, next-generation immunotherapies, and precision-guided strategies, while embedding translational endpoints into trial design to address the complex biology and therapeutic resistance of GBM.
    Review • Journal • PARP Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • NTRK fusion
    |
    temozolomide • tasadenoturev (DNX-2401)
    1m
    Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration. (PubMed, J Immunother Precis Oncol)
    Enadenotucirev (EnAd) and successor transgene-armed Tumor-Specific Immuno-Gene (T-SIGn) vectors are replication-competent, blood-stable viral vectors that traffic to tumor sites following intravenous (IV) administration...The aggregated safety analysis revealed that safety and tolerability are defined by systemic viremia but not off-target or transgene-related toxicities. Nucleic acid and cytokine release from tumors and changes in the TME (e.g., CD8+ T cells), indicative of the mechanism of action of replication-competent viral vectors, constitute potentially valuable data to support the definition of a recommended phase 2 dose and the assessment of the benefit of multicycle administration.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CCL2 (Chemokine (C-C motif) ligand 2) • IL17A (Interleukin 17A)
    |
    enadenotucirev (ColoAd1)
    2ms
    IL-8-Induced Tumor Self-Rampart Spatially Confines Oncolytic Virotherapy in Glioblastoma. (PubMed, Neuro Oncol)
    Glioblastoma mounts a spatial self-protective defense through IL-8-driven TSR formation that restricts oncolytic virus spread. IL-8 functions as both a pharmacodynamic biomarker and a therapeutic target, and its inhibition provides a rational strategy to overcome resistance and optimize GBM virotherapy.
    Journal • IO biomarker
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    YSCH-01 • reparixin (DF 1681Y)
    2ms
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Shanghai Virogin Biotech Co., Ltd.
    New P1 trial
    2ms
    A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. (clinicaltrials.gov)
    P1/2, N=30, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    2ms
    A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | N=27 --> 0 | Enrolling by invitation --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide